北京大学学报(医学版) ›› 2023, Vol. 55 ›› Issue (6): 1053-1057. doi: 10.19723/j.issn.1671-167X.2023.06.015

• 论著 • 上一篇    下一篇

合并胎儿心脏病变的抗SSA抗体阳性孕妇的临床及实验室特征

李宇菲1,闫亚妮2,靳家扬1,李春1,*(),裴秋艳2,*()   

  1. 1. 北京大学人民医院风湿免疫科,北京 100044
    2. 北京大学人民医院妇产科,北京 100044
  • 收稿日期:2023-08-22 出版日期:2023-12-18 发布日期:2023-12-11
  • 通讯作者: 李春,裴秋艳 E-mail:fiona_leechun@163.com;pqypei@126.com
  • 基金资助:
    中华国际医学交流基金会(Z-2018-40-2101);北京大学人民医院研究与发展基金(RD 2022-66)

Clinical characteristics of fetal cardiac disease in patients with anti-SSA antibody positive

Yu-fei LI1,Ya-ni YAN2,Jia-yang JIN1,Chun LI1,*(),Qiu-yan PEI2,*()   

  1. 1. Department of Rheumatology and Immunology, Peking University People' s Hospital, Beijing 100044, China
    2. Department of Obstetrics & Gynecology, Peking University People' s Hospital, Beijing 100044, China
  • Received:2023-08-22 Online:2023-12-18 Published:2023-12-11
  • Contact: Chun LI,Qiu-yan PEI E-mail:fiona_leechun@163.com;pqypei@126.com
  • Supported by:
    China lnternational Medical Foundation(Z-2018-40-2101);Peking University People' s Hospital Scientific Research Development Funds(RD 2022-66)

RICH HTML

  

摘要:

目的: 探究合并胎儿心脏病变的抗干燥综合征相关抗原A(Sjögren’s-syndrome-related antigen A, SSA)抗体阳性孕妇的临床表现、实验室指征及药物特征。方法: 在2013年1月至2023年7月于北京大学人民医院就诊且最终确诊自身免疫病的孕妇中, 选择抗SSA抗体阳性且超声确诊胎儿心脏病变的患者作为病变组, 抗SSA抗体阳性且超声检查无胎儿心脏病变的患者作为对照组, 收集两组患者的临床、实验室及用药信息, 比较组间基线数据无差异后对其临床指标进行统计学分析。结果: 合并胎儿心脏病变的抗SSA抗体阳性患者共11例, 其中有先天性房室传导阻滞表现者共7例, 是最常见的胎儿心脏病变类型。病变组患者孕前确诊自身免疫病的比例显著低于对照组(P=0.032), 多因胎儿心脏病变首次进行相关免疫学检查。病变组患者孕期白细胞水平[(9.29±2.58)×109/L vs. (7.10±1.90)×109/L, t=3.052, P=0.004]、红细胞沉降率[49.50(48.00, 51.00) mm/h vs. 23.00(15.00, 30.25) mm/h, Z=-2.251, P=0.024]、IgA水平[3.46(2.30, 5.06) g/L vs. 2.13(1.77, 2.77) g/L, Z=-2.181, P=0.029]、抗核抗体(antinuclear antibody, ANA)滴度[1∶320(1∶160, 1∶320) vs. 1∶80(1∶40, 1∶160), Z=-3.022, P=0.003]显著高于对照组。组间孕期合并SSB抗体阳性的比例(37.5% vs. 7.7%, P=0.053)、羟氯喹使用剂量及起用时间差异均无统计学意义。病变组孕期使用激素的比例及剂量显著高于对照组(P<0.05), 其中孕早期两组间差异无统计学意义, 而孕中期、孕晚期病变组激素使用剂量显著高于对照组。结论: 胎儿心脏病变是一种罕见但与抗SSA抗体阳性高度相关的胎儿畸形, 孕期白细胞、红细胞沉降率、IgA水平及ANA滴度显著升高的患者胎儿心脏病变发生的风险更高。胎儿房室传导阻滞一旦发生便难以逆转, 因此, 预防和监测的重要性高于补救治疗。

关键词: 抗SSA抗体, 先天性心脏缺损, 心脏传导阻滞, 妊娠, 危险因素

Abstract:

Objective: To investigate the clinical manifestations and laboratory indicators of anti-Sjögren's-syndrome-related antigen A (SSA) antibody associated fetal cardiac disease. Methods: Pregnant women hospitalized at Peking University People's Hospital from January 2013 to July 2023 were included. Eleven patients with anti-SSA antibody positive were eventually diagnosed with fetal cardiac di-sease. And patients with anti-SSA antibody positive without fetal cardiac disease were selected as controls. Clinical manifestations, laboratory indications and drug usage were compared between the two groups. Results: Among these 11 patients, congenital heart block was confirmed in seven, which was the most common manifestations of fetal cardiac malformation. The proportion of the patients diagnosed with autoimmune disease before pregnancy in fetal cardiac malformation group was significantly lower than that in the control group (P=0.032), while most of the patients in the fetal cardiac malformation group received immune-related examinations for the first time because of this time's fetal cardiac diagnosis. While most of the patients in the control group received routine examinations because of autoimmune diseases diagnosed before pregnancy. During pregnancy, the white blood cell level [(9.29±2.58)×109/L vs. (7.10±1.90×109/L, t=3.052, P=0.004], erythrocyte sedimentation rate [(49.50 (48.00, 51.00) mm/h vs. 23.00 (15.00, 30.25) mm/h, Z=-2.251, P=0.024], IgA level [3.46 (2.30, 5.06) g/L vs. 2.13 (1.77, 2.77) g/L, Z=-2.181, P=0.029], and antinuclear antibody (ANA) titers [1∶320 (1∶160, 1∶320) vs. 1∶80 (1∶40, 1∶160), Z=-3.022, P=0.003] were significantly higher in fetal cardiac malformation group than in the control group. The proportion of positive anti-SSB antibody during pregnancy did not show a statistically significant difference between the two groups (37.5% vs. 7.7%, P=0.053). There was no significant difference in hydroxychloroquine dosage and initiation time between the two groups. The dosage of prednisone in the second and third trimesters was significantly higher in the cardiac malformation group than that in the control group, but there was no significant difference in the first trimester. Conclusion: Fetal cardiac disease is rare in pregnant women with anti-SSA antibody. White blood cell, erythrocyte sedimentation rate, IgA, the titer of ANA positivity were higher in the fetal heart disease group during pregnancy. Since congenital heart block is difficult to reverse, its prevention and monitoring are more important than remedial treatment.

Key words: Anti-Sjögren's-syndrome-related antigen A antibody, Congenital heart defects, Heart block, Pregnancy, Risk factors

中图分类号: 

  • R593.2

表1

病变组及对照组的临床表现及孕期合并疾病比较"

Parameters Cardiac malformation (n=11) Control (n=44) P
Clinical feature, n(%)
  History of miscarriage 5 (45.5) 22 (50.0) > 0.999
  Leukopenia during pregnancy 0 7 (15.9) 0.323
  Thrombocytopenia during pregnancy 2 (18.2) 10 (22.7) > 0.999
  Diagnosis of autoimmune disease before pregnancy 6 (54.5) 38 (86.4) 0.032
Complicating disease, n(%)
  Hashimoto thyroiditis 2 (18.2) 2 (4.5) 0.175
  Hyperthyroidism 0 0 > 0.999
  Hypothyroidism 1 (9.1) 8 (18.2) 0.669
  Gestational diabetes mellitus 1 (9.1) 3 (6.8) > 0.999
  Ovarian tumor 0 2 (4.5) > 0.999

表2

心脏畸形组和对照组孕期实验室指标比较"

Parameters Cardiac malformation (n=11) Control (n=44) Z/t/χ2 P
WBC during pregnancy/(×109/L) 9.29±2.58 7.10±1.90 3.052 0.004
PLT during pregnancy/(×109/L) 202.20±79.05 171.51±56.68 1.428 0.159
ESR during pregnancy/(mm/h) 49.50 (48.00, 51.00) 23.00 (15.00, 30.25) -2.251 0.024
IgA during pregnancy/(g/L) 3.46 (2.30, 5.06) 2.13 (1.77, 2.77) -2.181 0.029
ANA positive during pregnancy 10/10 (100.0) 38/40 (95.0) > 0.999
ANA titer during pregnancy 1∶320 (1∶160, 1∶320) 1∶80 (1∶40, 1∶160) -3.022 0.003
Anti-SSB positive during pregnancy 3/8 (37.5) 3/39 (7.7) 0.053

表3

心脏畸形组和对照组的用药情况比较"

Parameters Cardiac malformation (n=11) Control (n=44) Z/t/χ2 P
HCQ
  Use of HCQ during pregnancy, n(%) 10 (90.9) 35 (79.5) 0.667
  Use of HCQ during the first trimester, n(%) 6 (54.5) 33 (75.0) 0.266
  HCQ dose in the first trimester/mg, M (P25, P75) 200 (0, 200) 200 (25, 200) -1.117 0.264
  HCQ dose in the second trimester/mg, M (P25, P75) 200 (200, 200) 200 (100, 200) -0.555 0.579
  HCQ dose in the third trimester/mg, M (P25, P75) 200 (200, 200) 200 (125, 200) -1.098 0.272
Prednisone
  Use of prednisone during pregnancy, n(%) 9 (81.8) 16 (36.4) 0.015
  Prednisone dose in the first trimester/mg, M (P25, P75) 0 (0, 10.00) 0 (0, 5.00) -0.593 0.553
  Prednisone dose in the second trimester/mg, M (P25, P75) 10.00 (0, 20.00) 0 (0, 5.00) -2.924 0.003
  Prednisone dose in the third trimester/mg, M (P25, P75) 10.00 (5.00, 26.70) 0 (0, 5.00) -3.347 0.001
1 Yuan T , Shuo Y , Qi L , et al. Pregnancy-related complications in systemic lupus erythematosus[J]. J Autoimmun, 2022, 132, 102864.
doi: 10.1016/j.jaut.2022.102864
2 Merz WM , Fischer-Betz R , Hellwig K , et al. Pregnancy and autoimmune disease[J]. Dtsch Arztebl Int, 2022, 119 (9): 145- 156.
3 Fausta B , Camilla B , Irene MD , et al. Impact of pregnancy on progression of preclinical autoimmune disorders: A prospective cohort study[J]. Rheumatology (Oxford), 2022, 62 (9): 2971- 2978.
4 Marder W , Littlejohn EA , Somers EC . Pregnancy and autoimmune connective tissue disease[J]. Best Pract Res Clin Rheumatol, 2016, 30 (1): 63- 80.
doi: 10.1016/j.berh.2016.05.002
5 Fischer-Betz R , Specker C . Pregnancy in systemic lupus erythematosus and antiphospholipid syndrome[J]. Best Pract Res Clin Rheumatol, 2017, 31 (3): 397- 414.
doi: 10.1016/j.berh.2017.09.011
6 李珊, 李明, 张旭. 19例新生儿红斑狼疮的心血管表现[J]. 广州医药, 2022, 53 (6): 48- 51.
7 Julkunen H , Eronen M . Long-term outcome of mothers of children with isolated heart block in Finland[J]. Arthritis Rheum, 2001, 44 (3): 647- 652.
doi: 10.1002/1529-0131(200103)44:3<647::AID-ANR113>3.0.CO;2-I
8 Izmirly MP , Saxena A , Kim YM , et al. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus[J]. Circulation, 2011, 124 (18): 1927- 1935.
doi: 10.1161/CIRCULATIONAHA.111.033894
9 Saxena A , Izmirly PM , Bomar RP , et al. Factors associated with long-term cardiac dysfunction in neonatal lupus[J]. Ann Rheum Dis, 2020, 79 (2): 217- 224.
doi: 10.1136/annrheumdis-2019-215900
10 Habib SM , Vermeer MH . A baby with red plaques on the face and a first-degree heart block: Neonatal lupus[J]. Lancet, 2020, 396 (10260): 1432.
doi: 10.1016/S0140-6736(20)32176-0
11 Wainwright B , Bhan R , Trad C , et al. Autoimmune-mediated congenital heart block[J]. Best Pract Res Clin Obstet Gynaecol, 2020, 64, 41- 51.
doi: 10.1016/j.bpobgyn.2019.09.001
12 Brito-Zerón P , Izmirly PM , Ramos-Casals M , et al. The clinical spectrum of autoimmune congenital heart block[J]. Nat Rev Rheumatol, 2015, 11 (5): 301- 312.
doi: 10.1038/nrrheum.2015.29
13 Aurélie A , Vijole D , Jeongsook P , et al. Anti-Ro52 monoclonal antibodies specific for amino acid 200-239, but not other Ro52 epitopes, induce congenital heart block in a rat model[J]. Ann Rheum Dis, 2012, 71 (3): 448- 454.
doi: 10.1136/annrheumdis-2011-200414
14 Llanos C , Friedman DM , Saxena A , et al. Anatomical and pathological findings in hearts from fetuses and infants with cardiac manifestations of neonatal lupus[J]. Rheumatology (Oxford), 2012, 51 (6): 1086- 1092.
doi: 10.1093/rheumatology/ker515
15 Cuneo BF , Strasburger JF , Niksch A , et al. An expanded phenotype of maternal SSA/SSB antibody-associated fetal cardiac disease[J]. J Matern Fetal Neonatal Med, 2009, 22 (3): 233- 238.
doi: 10.1080/14767050802488220
16 Tunks DR , Clowse EM , Miller GS , et al. Maternal autoantibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents[J]. Am J Obstet Gynecol, 2013, 208 (1): 64.e1- 64.e7.
doi: 10.1016/j.ajog.2012.09.020
17 Jaeggi E , Laskin C , Hamilton R , et al. The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus a prospective study of 186 antibody-exposed fetuses and infants[J]. J Am Coll Cardiol, 2010, 55 (24): 2778- 2784.
doi: 10.1016/j.jacc.2010.02.042
18 Shinohara K , Miyagawa S , Fujita T , et al. Neonatal lupus erythematosus: Results of maternal corticosteroid therapy[J]. Obstet Gynecol, 1999, 93 (6): 952- 957.
19 刘蕾, 华益民, 周开宇. 新生儿狼疮综合征诊疗研究进展[J]. 中国循证儿科杂志, 2018, 13 (3): 231- 235.
20 Izmirly P , Kim M , Friedman MD , et al. Hydroxychloroquine to prevent recurrent congenital heart block in fetuses of anti-SSA/Ro-positive mothers[J]. J Am Coll Cardiol, 2020, 76 (3): 292- 302.
doi: 10.1016/j.jacc.2020.05.045
21 Julie B , Nathalie C , Adey B , et al. Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus[J]. Ann Rheum Dis, 2018, 77 (12): 1742- 1749.
doi: 10.1136/annrheumdis-2018-213718
22 Strasburger FJ , Wacker-Gussmann A . Congenital heart block in subsequent pregnancies of SSA/Ro-positive mothers[J]. J Am Coll Cardiol, 2020, 76 (3): 303- 305.
doi: 10.1016/j.jacc.2020.05.052
23 Friedman DM , Kim MY , Copel JA , et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: The PR Interval and Dexamethasone Evaluation (PRIDE) prospective study[J]. Circulation, 2008, 117 (4): 485- 493.
24 Gleicher N , Elkayam U . Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: A review of published literature and registered clinical trials[J]. Autoimmun Rev, 2013, 12 (11): 1039- 1045.
25 张利, 米荣, 王晓颖, 等. 静脉注射人免疫球蛋白治疗45例新生儿红斑狼疮的疗效[J]. 中国新药与临床杂志, 2023, 42 (6): 378- 382.
[1] 颜野,李小龙,夏海缀,朱学华,张羽婷,张帆,刘可,刘承,马潞林. 前列腺癌根治术后远期膀胱过度活动症的危险因素[J]. 北京大学学报(医学版), 2024, 56(4): 589-593.
[2] 陈延,李况蒙,洪锴,张树栋,程建星,郑仲杰,唐文豪,赵连明,张海涛,姜辉,林浩成. 阴茎海绵体注射试验对阴茎血管功能影响的回顾性研究[J]. 北京大学学报(医学版), 2024, 56(4): 680-686.
[3] 庞博,郭桐君,陈曦,郭华棋,石嘉章,陈娟,王欣梅,李耀妍,单安琪,余恒意,黄婧,汤乃军,王艳,郭新彪,李国星,吴少伟. 天津与上海35岁以上人群氮氧化物个体暴露水平及其影响因素[J]. 北京大学学报(医学版), 2024, 56(4): 700-707.
[4] 和静,房中则,杨颖,刘静,马文瑶,霍勇,高炜,武阳丰,谢高强. 血浆中脂质代谢分子与颈动脉粥样硬化斑块、传统心血管危险因素及膳食因素的关系[J]. 北京大学学报(医学版), 2024, 56(4): 722-728.
[5] 蔡珊,张依航,陈子玥,刘云飞,党佳佳,师嫡,李佳欣,黄天彧,马军,宋逸. 北京市中小学生身体活动时间现状及影响因素的路径[J]. 北京大学学报(医学版), 2024, 56(3): 403-410.
[6] 张祖洪,陈天娇,马军. 中小学生青春发动时相与心血管代谢危险因素的相关性[J]. 北京大学学报(医学版), 2024, 56(3): 418-423.
[7] 林郁婷,王华丽,田宇,巩俐彤,常春. 北京市老年人认知功能的影响因素[J]. 北京大学学报(医学版), 2024, 56(3): 456-461.
[8] 马会超,李军,王永清. 妊娠合并炎症性肠病的临床特点[J]. 北京大学学报(医学版), 2024, 56(2): 260-266.
[9] 朱金荣,赵亚娜,黄巍,赵微微,王悦,王松,苏春燕. 感染新型冠状病毒的血液透析患者的临床特征[J]. 北京大学学报(医学版), 2024, 56(2): 267-272.
[10] 赖展鸿,李嘉辰,贠泽霖,张永刚,张昊,邢晓燕,邵苗,金月波,王乃迪,李依敏,李玉慧,栗占国. 特发性炎性肌病完全临床应答相关因素的单中心真实世界研究[J]. 北京大学学报(医学版), 2024, 56(2): 284-292.
[11] 司筱芊,赵秀娟,朱凤雪,王天兵. 创伤出血性休克后急性呼吸窘迫综合征的危险因素[J]. 北京大学学报(医学版), 2024, 56(2): 307-312.
[12] 李洋洋,侯林,马紫君,黄山雅美,刘捷,曾超美,秦炯. 孕期因素与婴儿牛奶蛋白过敏的关系[J]. 北京大学学报(医学版), 2024, 56(1): 144-149.
[13] 刘晓强,周寅. 牙种植同期植骨术围术期高血压的相关危险因素[J]. 北京大学学报(医学版), 2024, 56(1): 93-98.
[14] 罗靓,李云,王红彦,相晓红,赵静,孙峰,张晓盈,贾汝琳,李春. 抗内皮细胞抗体检测在早期流产中的预测价值[J]. 北京大学学报(医学版), 2023, 55(6): 1039-1044.
[15] 游芳凝,罗靓,刘香君,张学武,李春. 未分化结缔组织病患者的妊娠结局、疾病演变及其影响因素[J]. 北京大学学报(医学版), 2023, 55(6): 1045-1052.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 杨天智, 陈大兵, 张强. 不同吸收促进剂及酶抑制剂对胰岛素体内及体外口腔黏膜渗透性的影响[J]. 北京大学学报(医学版), 2001, 33(3): 238 -242 .
[2] 柳晓辉, 那加, 刘玲玲, 罗斌. 头颈部血管肉瘤3例[J]. 北京大学学报(医学版), 2001, 33(3): 288 -289 .
[3] 梁成, 王兴, 伊彪, 李自力, 王晓霞. 骨性颞下颌关节强直伴小颌畸形及阻塞性睡眠呼吸暂停综合征的牵引成骨治疗[J]. 北京大学学报(医学版), 2002, 34(2): 112 -116 .
[4] 郭应禄, 张凯. 临床研究所要创高水平医疗[J]. 北京大学学报(医学版), 2002, 34(5): 431 -433 .
[5] 方鹏骞, 徐娟, 张佳慧, 李翠, 杨芳, 孔鹏, 孙杨. 艾滋病高危人群规模间接估计方法的应用及其结果的外推研究[J]. 北京大学学报(医学版), 2008, 40(2): 214 -218 .
[6] 胡维亨, 任军. 人乙型肝炎病毒DNA阳性血清对人骨髓间充质干细胞向肝细胞分化的影响[J]. 北京大学学报(医学版), 2008, 40(5): 459 -464 .
[7] 龚继芳, 袁艳华, 宋国红, 余靖, 贾军, 任军. CD44+/CD24-/low/ABCG2-乳腺癌干细胞比例增高与临床治疗相关的探索性研究[J]. 北京大学学报(医学版), 2008, 40(5): 465 -470 .
[8] 邸立军, 任军, 宋国红, 余靖, 方健, 车利, 祝毓琳. 自体外周血CD34+干细胞来源树突状细胞体外扩增治疗恶性体腔积液[J]. 北京大学学报(医学版), 2008, 40(5): 486 -488 .
[9] 张勇, 栾庆先. 牙周维护治疗在保持牙周长期疗效中的作用[J]. 北京大学学报(医学版), 2011, 43(1): 29 -33 .
[10] 曾百进, 余日月, 周永胜, 徐军, 倪永伟, 刘云松, 许永伟. rhTNF-α对成骨向分化前后的人脂肪基质细胞分泌血管生成相关生长因子的影响[J]. 北京大学学报(医学版), 2009, 41(5): 565 -570 .